Cytokinetics Inc (CYTK) concluded trading on Wednesday at a closing price of $40.25, with 4.59 million shares of worth about $184.87 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -23.77% during that period and on April 03, 2025 the price saw a gain of about 7.33%. Currently the company’s common shares owned by public are about 118.21M shares, out of which, 115.43M shares are available for trading.
Stock saw a price change of -7.75% in past 5 days and over the past one month there was a price change of -7.87%. Year-to-date (YTD), CYTK shares are showing a performance of -14.43% which decreased to -44.88% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $37.46 but also hit the highest price of $75.71 during that period. The average intraday trading volume for Cytokinetics Inc shares is 1.64 million. The stock is currently trading -7.07% below its 20-day simple moving average (SMA20), while that difference is down -11.26% for SMA50 and it goes to -21.51% lower than SMA200.
Cytokinetics Inc (NASDAQ: CYTK) currently have 118.21M outstanding shares and institutions hold larger chunk of about 109.78% of that.
The stock has a current market capitalization of $4.77B and its 3Y-monthly beta is at 0.82. It has posted earnings per share of -$5.28 in the same period. It has Quick Ratio of 6.17. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CYTK, volatility over the week remained 6.67% while standing at 5.26% over the month.
Stock’s fiscal year EPS is expected to drop by -8.38% while it is estimated to increase by 18.06% in next year. EPS is likely to grow at an annualized rate of 19.31% for next 5-years, compared to annual growth of -20.02% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on February 07, 2025 offering a Buy rating for the stock and assigned a target price of $86 to it. Coverage by Stifel stated Cytokinetics Inc (CYTK) stock as a Buy in their note to investors on January 22, 2025, suggesting a price target of $80 for the stock. On November 08, 2024, RBC Capital Mkts Initiated their recommendations, while on August 13, 2024, Goldman Downgrade their ratings for the stock with a price target of $60. Stock get a Neutral rating from UBS on January 24, 2024.
